News

All Categories

08 October 2012

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

Media Release

03 September 2012

Hatchtech announce successful End-of-Phase 2 for head lice product DeOvo™

Media Release

08 August 2012

Virtual patient gets funding injection

Sydney Morning Herald

08 August 2012

Garrett acts out NBN potential

Sydney Morning Herald

15 July 2012

Digital tools can reshape our methods

Sydney Morning Herald

17 April 2012

Best Venture Capital Investment at the 2012 Vaccine Industry Excellence Awards

Awards, Media Release

09 February 2012

Vaxxas featured in BRW Top 10 start ups to watch

Awards

08 December 2011

Vaxxas wins Australian Innovation Challenge Awards

Awards

26 October 2010

Hatchtech raises $6.3m for DeOvo™ Head Lice Phase 2b Clinical Trial

Media Release

20 September 2010

Vaxxas wins Australian Research Council Eureka Prize

Awards

09 April 2010

Feds seek more funds for innovation program

Uncategorized

30 March 2010

Former i.lab CEO joins OneVentures investment team

Uncategorized

29 March 2010

New venture capital fund with $40m to spend

Uncategorized

29 March 2010

New venture capital fund launches for tech companies with revenue under $5 million

Smart Company

23 March 2010

$40m in venture capital for tech

Uncategorized

21 June 2006

Hatchtech wins prize for best Victorian technology commercialisation from all industries

Awards

21 June 2006

Hatchtech wins Commercialisation Expo 2006 Prize for Best Australian Life Sciences Company

Awards

decor decor decor
decor decor decor decor decor